Diabetes Beyond Blood Glucose: The Microvascular and Tissue-Repair Dimensions
The disease is more than one number
HbA1c is clinically valuable because chronic hyperglycemia contributes to long-term complications. But glucose measurement does not directly image retinal capillaries, renal glomerular architecture, peripheral nerve injury or local wound oxygenation. People with similar average glucose may differ in disease duration, blood pressure, lipoprotein exposure, susceptibility and cumulative tissue damage. These differences help explain why the complication burden is not identical across patients.
Microvasculature as a mediator
Diabetic retinopathy, nephropathy and neuropathy involve tissue-specific injury that may include endothelial dysfunction, basement membrane alterations, impaired perfusion and inflammation. In wounds, perfusion, neuropathy, immune defense and mechanical pressure can interact. These are mechanistic layers between metabolic exposure and clinical disability—not arguments that blood glucose is irrelevant.
Time creates lag
An improved metabolic state may reduce the rate of future injury yet leave existing fibrosis, nephron loss or axonal injury in place. Therefore short-term biochemical success and long-term tissue recovery should be measured separately. A person may feel little immediate change while reducing future complication risk, which is a powerful reason not to disparage established treatment because symptoms persist.
The proposed integrated assessment
We propose using disease-specific measures of tissue function alongside standard metabolic and cardiovascular measures, rather than replacing one with the other. Examples include retinal examinations, kidney function and albuminuria assessment, neurological examinations, vascular evaluations and foot-risk assessments when indicated. These tools already exist; the novelty would be a more explicit narrative linking them to states of injury and repair.
Alternative explanations
Not every complication in a person with diabetes is caused by diabetes. Inherited neuropathies, vascular occlusions, medications and other conditions may mimic diabetic complications. Conversely, vascular risk in diabetes is often influenced by blood pressure, smoking and apoB-containing lipoproteins. A whole-system model must retain these discriminations rather than claiming a single metabolic-bile-vascular cascade.
Clinical boundary
Lifestyle or fasting interventions cannot be portrayed as safe substitutes for indicated insulin or other treatments. Sudden medication changes can cause severe hypo- or hyperglycemia and ketoacidosis. The essential insight is that glycemic control is necessary to understand but may not fully describe the trajectory of tissue injury.
Vascular injury persists on a different clock
Glucose fluctuations, blood pressure exposure and lipoprotein-associated vascular risk act over months and years. Retinal microaneurysms, nerve damage or glomerular structural injury can retain a history of those exposures. Better contemporary numbers may lower progression risk even if anatomy does not immediately normalize. This difference should shape patient expectations and scientific reporting: prevention of further harm is a clinically major benefit, not evidence of incomplete or superficial medicine.
Why 'reversing diabetes' requires careful language
Remission of type 2 diabetes can be defined using specified glycemic criteria without glucose-lowering drugs, but remission of hyperglycemia does not erase all accumulated complication risk or guarantee permanent normal insulin physiology. Type 1 diabetes has an entirely different insulin-deficiency mechanism. A volume concerning tissue repair should not use the phrase 'diabetes reversal' without specifying disease type, metabolic state, complications and the time frame of observation.
A research question worth pursuing
Which tissue markers predict remaining risk after glycemic improvement, and which mechanisms are modifiable? This could involve retinal changes, albuminuria, renal function, vascular stiffness, neuropathic deficits or wound healing. The hypothesis is not that these should replace established markers, but that integrating structural and functional measures can improve the precision of recovery claims.
Selected scientific reading
- Reitsma S et al. The endothelial glycocalyx: composition, functions, and visualization. Pflugers Arch. 2007.
- Østergaard L et al. Microcirculatory dysfunction and tissue oxygenation in critical illness. Acta Anaesthesiol Scand. 2015;59:1246–1259.
- Liu F et al. Mechanosignaling through YAP and TAZ drives fibroblast activation and fibrosis. Am J Physiol Lung Cell Mol Physiol. 2015.